TW202014192A - 神經類固醇衍生物及其用途 - Google Patents

神經類固醇衍生物及其用途 Download PDF

Info

Publication number
TW202014192A
TW202014192A TW108115447A TW108115447A TW202014192A TW 202014192 A TW202014192 A TW 202014192A TW 108115447 A TW108115447 A TW 108115447A TW 108115447 A TW108115447 A TW 108115447A TW 202014192 A TW202014192 A TW 202014192A
Authority
TW
Taiwan
Prior art keywords
item
pharmaceutical composition
patent application
application scope
ganaxolone
Prior art date
Application number
TW108115447A
Other languages
English (en)
Chinese (zh)
Inventor
納坦 布萊森
艾維納許 宣得 薩瑪
Original Assignee
加拿大商阿爾宙斯製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商阿爾宙斯製藥有限公司 filed Critical 加拿大商阿爾宙斯製藥有限公司
Publication of TW202014192A publication Critical patent/TW202014192A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108115447A 2018-05-04 2019-05-03 神經類固醇衍生物及其用途 TW202014192A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667100P 2018-05-04 2018-05-04
US62/667,100 2018-05-04

Publications (1)

Publication Number Publication Date
TW202014192A true TW202014192A (zh) 2020-04-16

Family

ID=68384780

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108115447A TW202014192A (zh) 2018-05-04 2019-05-03 神經類固醇衍生物及其用途

Country Status (11)

Country Link
US (2) US20190337975A1 (enExample)
EP (1) EP3788055A4 (enExample)
JP (1) JP2021523938A (enExample)
CN (1) CN112823164A (enExample)
AR (1) AR116659A1 (enExample)
AU (1) AU2019264032A1 (enExample)
CA (1) CA3099089A1 (enExample)
PY (1) PY1934080A (enExample)
TW (1) TW202014192A (enExample)
UY (1) UY38213A (enExample)
WO (1) WO2019211668A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7810970B2 (ja) * 2020-02-05 2026-02-04 シーポート・セラピューティクス・インコーポレイテッド 神経ステロイドの脂質プロドラッグ
WO2021174205A1 (en) * 2020-02-27 2021-09-02 Brii Biosciences, Inc. Prodrugs of neuroactive steroids
IL315509A (en) * 2022-03-18 2024-11-01 Marinus Pharmaceuticals Inc Genaxolone medication matrims
CN119632996A (zh) * 2024-12-06 2025-03-18 北京华睿鼎信科技有限公司 神经甾体衍生物固体分散体及制备方法和应用、中枢神经系统障碍相关病症的治疗药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB748846A (en) * 1953-10-28 1956-05-09 Vitamins Ltd A process for the manufacture of pregnan-3(-a)-ol-20-one and derivatives thereof
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
WO2006010085A1 (en) * 2004-07-09 2006-01-26 Roxro Pharma, Inc. Use of neurosteroids to treat neuropathic pain
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US20170022245A1 (en) * 2013-11-26 2017-01-26 Biopharma Works Ganaxolone derivatives for treatment of central nervous systems disorders
AU2018290348B2 (en) * 2017-06-23 2024-04-04 Ayikoe-Guy MENSAH-NYAGAN Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
CN109666055A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 调节中枢神经治疗抑郁症的化合物及其用途

Also Published As

Publication number Publication date
US20190337975A1 (en) 2019-11-07
PY1934080A (es) 2019-11-08
AR116659A1 (es) 2021-06-02
EP3788055A4 (en) 2022-03-30
UY38213A (es) 2019-10-31
JP2021523938A (ja) 2021-09-09
EP3788055A2 (en) 2021-03-10
US20210363173A1 (en) 2021-11-25
AU2019264032A1 (en) 2020-12-03
CN112823164A (zh) 2021-05-18
CA3099089A1 (en) 2019-11-07
WO2019211668A2 (en) 2019-11-07
WO2019211668A3 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
US20210363173A1 (en) Neurosteriod derivatives and uses thereof
US3711606A (en) Enhancing tissue penetration of physiologically active steroidal agents with dmso
WO2017208072A2 (en) Nasal cannabidiol compositions
EP0974350A1 (en) External preparation containing tranilast and process for producing the same
WO2022160970A1 (zh) 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液
JP2021523938A5 (enExample)
TWI473615B (zh) 局部藥學組成物
US20260097050A1 (en) Nasal cannabidiol compositions
CN113749986A (zh) 一种乳木果油敏感肌肤全效修护乳液及其制备方法和应用
US20200188412A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
EP0001851B1 (en) Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
WO2020051644A1 (en) Treatment of peripheral nervous tissue inflammation
JP2015503573A (ja) ベキサロテンおよびコルチコステロイドを含む局所用医薬組成物
TWI903311B (zh) 局部藥物組合物、其製備方法及其在醫藥上的用途
WO2025260550A1 (zh) 一种黄体酮自乳化制剂及其制备方法和应用
EP3795146B1 (en) Pain-relieving and anti-inflammatory composition for local use
WO2016161683A1 (zh) 一种他汀类药物组合物及胶囊制剂、其制备方法
US11576920B2 (en) Composition and method to aid in hormone replacement therapy
GB2542872A (en) Use of heptyl glucoside as skin penetration enhancer in transdermal pharmaceutical compositions
EP3192515B1 (de) Pharmazeutische zusammensetzung enthaltend 7beta-hydroxycholesterol geeignet zur intravenösen verabreichung
CN118267355A (zh) 一种辣椒素的乳剂组合物及其制备方法和应用
CN101513411A (zh) 齐墩果烷-28-酸-2,11,13(18)-三烯在制备治疗皮肤疾病药物中的应用
CN106361686A (zh) 一种碘硝酚的透皮制剂及其制备方法与药物应用
AU2021236517A1 (en) Composition and method to aid in hormone replacement therapy
CN101756995A (zh) 11,28-二羟基-齐墩果烷-2,12-二烯在制备治疗皮肤疾病药物中的应用